Study meets primary endpoint in patients living with type 1 SMA To date, more than 400 patients have been treated with risdiplam across all studies, with no treatment related safety findings leading to study withdrawal in any risdiplam trial Risdiplam PDUFA expected...
BOULDER, Colo., Jan. 23, 2020 (GLOBE NEWSWIRE) — miRagen Therapeutics Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that it will present new...
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that both batches of the company’s manufactured...
— Phase 3 trial achieved its primary endpoint and all secondary endpoints with marked improvement in key indicators of disease — January 22, 2020 05:20 PM Eastern Standard Time DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP)...
NEW YORK, Jan. 22, 2020 /PRNewswire/ — By definition, an email drip campaign is a type of marketing process that entails the automated dissemination of emails. In addition to the ability to personalize messages, a drip campaign can be set to run during a...
TEL AVIV, Israel, Jan. 22, 2020 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today the completion of patient recruitment in the triple combination arm of its ongoing Phase 2a...
Email
Text